Close Menu

MALDI-TOF

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

Scientists from the Colorado School of Mines have proposed a method to complement mass spec-based protein profiling. 

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The UK firm is using MALDI-TOF mass spec technology to develop the test as a screening tool for the disorder as early as eight weeks into a pregnancy.

Researchers from the Public Health Agency of Sweden have developed an approach for typing Clostridium difficile isolates based on their patterns of high-molecular weight proteins.

MALDI mass spectrometry continues to make inroads into the microbiology market, with a growing number of researchers and clinicians adopting the technology for microbe identification.

NEW YORK (GenomeWeb News) – Ezose Sciences today said that it has signed an agreement to collaborate with Kyowa Hakko Kirin on glycomics studies using Ezose's GlycanMap platform.

NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.